Updated

Pharmaceutical distributor Cencora raised its full-year guidance and executed a $1 billion share buyback, moves that were initially well received but drew scrutiny from analysts questioning underlying drivers of the improved outlook. The buyback signals management's confidence in the company's cash generation. The report adds Cencora to a list of health care distribution companies navigating margin pressures while returning capital to shareholders.